Results 141 to 148 of about 26,375 (148)
ENERGY &ENVIRONMENTAL MATERIALS, EarlyView.Electromagnetic interference (EMI)‐shielding electrocardiogram (ECG) sensor was demonstrated for accurately monitoring human vital signals in real time. The hydrogel nanocomposite‐based ECG patch stably operated on human skin, showing excellent mechanical/electrical resilience and humidity stability.
Sang Yoon Park +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1203-1216, April 2025.The 366 patients diagnosed with transthyretin amyloidosis cardiomyopathy (ATTR‐CM) were analyzed regarding their clinical characteristics in the first year after approval of tafamidis 61 mg for ATTR‐CM in Germany. Nearly two‐thirds of the patients were in an advanced disease stage and 64% met the key criteria of the “Transthyretin Amyloidosis ...
Richard J. Nies +23 more
wiley +1 more source
A phenomap of TTR amyloidosis to aid diagnostic screening
ESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos +4 more
wiley +1 more source
ESC Heart Failure, EarlyView.Abbreviations: TAVI, transcatheter aortic valve implantation; ATTR‐CM, transthyretin cardiac amyloidosis. We aimed to diagnose occult ATTR‐CM in patients with severe aortic stenosis undergoing TAVI using bone scintigraphy. We verified a diagnosis of ATTR‐CM in 8 of 171 (4.7 %) consecutive aortic stenosis patients who underwent TAVI.
Margrethe Flesvig Holt +15 more
wiley +1 more source
Delays in diagnosis and treatment of ATTR cardiac amyloidosis: A real‐world data analysis
ESC Heart Failure, EarlyView.Abstract Aims and Background Cardiac amyloidosis leads to functional cardiac impairment and heart failure. Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the most common form. After initial suspicion, diagnosis involves imaging techniques, biopsy and genetic tests, prompting transthyretin stabilizer therapy to slow disease progression.
Julia Vogel +7 more
wiley +1 more source
Novel three‐dimensional ECG algorithm for reliable screening for cardiac amyloidosis
ESC Heart Failure, EarlyView.The present manuscript describes the derivation and validation of an algorithm for screening of cardiac amyloidosis using 3‐dimensional ECG. The algorithm is based on a ECG vector loop, acquired over the duration of 15 seconds using 4 electrodes. With this easy to perform method, we describe a high diagnostic accuracy for the detection of cardiac ...
Amir A. Mahabadi +8 more
wiley +1 more source